Reduction in morbidity of rotavirus induced diarrhoea in mice by yeast produced monovalent llama-derived antibody fragments
- PMID: 16616802
- DOI: 10.1016/j.vaccine.2006.02.045
Reduction in morbidity of rotavirus induced diarrhoea in mice by yeast produced monovalent llama-derived antibody fragments
Abstract
Apart from the use of oral rehydration solution, there are currently no treatment modalities for rotavirus induced diarrhoea, which is particularly relevant to developing countries. Fragments derived from llama heavy chain antibodies were previously shown to be highly stable, efficiently produced in yeast and exhibiting high epitope specific affinity. We now aim to demonstrate that these antibody fragments are capable of reducing morbidity of rotavirus induced diarrhoea. Here we show the isolation of rotavirus specific antibody fragments and their capability of reducing the morbidity of rotavirus induced diarrhoea in vivo in mice. They could provide a treatment modality for the moderation of human rotavirus infections having a significant impact on the course of an often fatal childhood disease.
Similar articles
-
Lactobacilli expressing variable domain of llama heavy-chain antibody fragments (lactobodies) confer protection against rotavirus-induced diarrhea.J Infect Dis. 2006 Dec 1;194(11):1580-8. doi: 10.1086/508747. Epub 2006 Oct 23. J Infect Dis. 2006. PMID: 17083044
-
Yeast expression of the VP8* fragment of the rotavirus spike protein and its use as immunogen in mice.Biotechnol Bioeng. 2006 Jan 5;93(1):89-98. doi: 10.1002/bit.20696. Biotechnol Bioeng. 2006. PMID: 16193515
-
Passive immunization of guinea pigs with llama single-domain antibody fragments against foot-and-mouth disease.Vet Microbiol. 2007 Mar 10;120(3-4):193-206. doi: 10.1016/j.vetmic.2006.10.029. Epub 2006 Oct 28. Vet Microbiol. 2007. PMID: 17127019
-
Rotavirus vaccines: recent developments and future considerations.Nat Rev Microbiol. 2007 Jul;5(7):529-39. doi: 10.1038/nrmicro1692. Nat Rev Microbiol. 2007. PMID: 17571094 Review.
-
Rotavirus vaccines: how they work or don't work.Expert Rev Mol Med. 2008 Feb 12;10:e5. doi: 10.1017/S1462399408000574. Expert Rev Mol Med. 2008. PMID: 18267049 Review.
Cited by
-
In vitro neutralisation of rotavirus infection by two broadly specific recombinant monovalent llama-derived antibody fragments.PLoS One. 2012;7(3):e32949. doi: 10.1371/journal.pone.0032949. Epub 2012 Mar 5. PLoS One. 2012. PMID: 22403728 Free PMC article.
-
Therapeutic Applications of Functional Nanomaterials for Prostatitis.Front Pharmacol. 2021 May 28;12:685465. doi: 10.3389/fphar.2021.685465. eCollection 2021. Front Pharmacol. 2021. PMID: 34140892 Free PMC article. Review.
-
Nanobodies in the fight against infectious diseases: repurposing nature's tiny weapons.World J Microbiol Biotechnol. 2024 May 21;40(7):209. doi: 10.1007/s11274-024-03990-4. World J Microbiol Biotechnol. 2024. PMID: 38771414 Free PMC article. Review.
-
Nanoscale warriors against viral invaders: a comprehensive review of Nanobodies as potential antiviral therapeutics.MAbs. 2025 Dec;17(1):2486390. doi: 10.1080/19420862.2025.2486390. Epub 2025 Apr 9. MAbs. 2025. PMID: 40201976 Free PMC article. Review.
-
Engineered single-domain antibodies with high protease resistance and thermal stability.PLoS One. 2011;6(11):e28218. doi: 10.1371/journal.pone.0028218. Epub 2011 Nov 30. PLoS One. 2011. PMID: 22140551 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical